Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R.sub.2 is OH or OP(O)(OH).sub.2; and R.sub.1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

##STR00001##

The compound represented by formula (1): ##STR00001##
wherein A, B, R.sup.1, and R.sup.2 are as defined in the description,
provides organic electroluminescence (EL) devices having a high emission efficiency when operated at low voltage and a long lifetime and electronic devices including such organic EL devices.

The compound represented by formula (1): ##STR00001##
wherein A, B, R.sup.1, and R.sup.2 are as defined in the description,
provides organic electroluminescence (EL) devices having a high emission efficiency when operated at low voltage and a long lifetime and electronic devices including such organic EL devices.

The present disclosure relates to organic electroluminescent devices. The organic electroluminescent device according to the present disclosure exhibits improved lifespan characteristics and progressive driving voltage by including at least one deuterated compound(s).

The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

This disclosure provides a family of compounds that absorb and fluoresce in the short wave infrared region (SWIR, optionally 1000 nm to 1300 nm), including hydrophilic compounds that exhibit absorption and emission spectral profiles in aqueous solutions substantially similar to those observed in organic solvents such as methanol or DMSO. The compounds can be chemically linked to biomolecules including proteins, nucleic acids, and therapeutic small molecules. The compounds are useful for imaging in a variety of medical, biological and diagnostic applications, including SWIR in vivo imaging of regions of interest within a mammal.

The compound represented by formula (1):

##STR00001##

wherein A, B, R.sup.1, and R.sup.2 are as defined in the description, provides organic electroluminescence (EL) devices having a high emission efficiency when operated at low voltage and a long lifetime and electronic devices including such organic EL devices.

The present invention generally relates to various dinaphthothiophene compounds and processes for preparing these compounds.

A method of synthesizing a fused heteroaromatic compound includes obtaining a first intermediate from a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2, obtaining a second intermediate including a ring having a chalcogen element from the first intermediate, and obtaining a fused heteroaromatic compound by a cyclization reaction of the second intermediate.